Past 10 year’s financial track record analysis by Moneyworks4me indicates that Entero Healthcare Solutions Ltd is a below average quality company.
The key valuation ratios of Entero Healthcare Solutions Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Entero Healthcare Solutions Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | -3.3% | -6.7% | -0.2% | 4.1% | - |
| Value Creation Index ⓘ | NA | NA | NA | -0.7 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 105 | 137 | 178 | 318 | 418 |
| Sales YoY Gr. | - | 30.9% | 29.4% | 79.1% | - |
| Adj EPS ⓘ | -1,838.3 | -106.4 | -30.3 | 8.8 | 17.1 |
| YoY Gr. | - | NA | NA | NA | - |
| BVPS (₹) ⓘ | -3,067.5 | -176.1 | -194.3 | 373.5 | 382.5 |
| Adj Net Profit ⓘ | -18.4 | -41 | -12.5 | 38.4 | 74 |
| Cash Flow from Ops. ⓘ | -68.2 | -44.7 | -56.9 | -75.7 | - |
| Debt/CF from Ops. ⓘ | 0 | -0.7 | -1.6 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 44.8% | 79.1% | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | NA | NA | NA | NA | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | -3.8 | -7.9 | -2.2 | 3.5 | 4.5 |
| Op. Profit Mgn % ⓘ | -30.5 | -39.1 | -24.7 | -10.8 | -6.1 |
| Net Profit Mgn % ⓘ | -17.6 | -29.8 | -7 | 12.1 | 17.8 |
| Debt to Equity ⓘ | 0 | 0.1 | 0.2 | 0 | 0 |
| Working Cap Days ⓘ | 0 | 1,130 | 1,109 | 856 | 650 |
| Cash Conv. Cycle ⓘ | 0 | 172 | 119 | 91 | 602 |
Return on Equity has increased versus last 3 years average to 4.50%
Sales growth is growing at healthy rate in last 3 years 44.77%
Sales growth is good in last 4 quarters at 76.05%
Net Profit has been subdued in last 3 years 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 17.1 | 16.4 |
| TTM Sales (₹ Cr.) | 418 | 4,425 |
| BVPS (₹.) ⓘ | 382.5 | 386.9 |
| Reserves (₹ Cr.) ⓘ | 1,620 | 1,639 |
| P/BV ⓘ | 3.62 | 3.58 |
| PE ⓘ | 80.99 | 84.38 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 974.45 / 1583.00 |
| All Time Low / High (₹) | 974.45 / 1583.00 |
| Market Cap (₹ Cr.) | 6,028 |
| Equity (₹ Cr.) | 43.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 69.9 |
| Pledged * | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Sales | 105 | 137 | 178 | 318 |
| Operating Expenses ⓘ | 137 | 191 | 222 | 353 |
| Manufacturing Costs | 1 | 1 | 1 | 1 |
| Material Costs | 98 | 128 | 155 | 270 |
| Employee Cost | 23 | 38 | 44 | 56 |
| Other Costs ⓘ | 15 | 24 | 23 | 26 |
| Operating Profit ⓘ | -32 | -54 | -44 | -34 |
| Operating Profit Margin (%) | -30.5% | -39.1% | -24.7% | -10.8% |
| Other Income ⓘ | 23 | 27 | 53 | 90 |
| Interest ⓘ | 2 | 5 | 11 | 22 |
| Depreciation ⓘ | 7 | 9 | 10 | 9 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -18 | -41 | -12 | 24 |
| Tax ⓘ | 0 | 0 | 0 | -14 |
| Profit After Tax | -18 | -41 | -12 | 38 |
| PAT Margin (%) | -17.3% | -29.8% | -7.0% | 12.1% |
| Adjusted EPS (₹) | -1,815.2 | -106.0 | -30.3 | 8.8 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 486 | 551 | 584 | 1,625 | ||||||
| Share Capital ⓘ | 517 | 623 | 668 | 43 | ||||||
| Reserves ⓘ | -31 | -72 | -84 | 1,581 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 0 | 30 | 92 | 0 | ||||||
| Long Term Debt | 0 | 0 | 28 | 0 | ||||||
| Short Term Debt | 0 | 30 | 64 | 0 | ||||||
| Trade Payables | 13 | 35 | 56 | 65 | ||||||
| Others Liabilities ⓘ | 33 | 38 | 33 | 65 | ||||||
| Total Liabilities ⓘ | 533 | 654 | 764 | 1,755 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 62 | 72 | 70 | 72 | ||||||
| Accumulated Depreciation | 12 | 21 | 29 | 38 | ||||||
| Net Fixed Assetsⓘ | 50 | 51 | 41 | 34 | ||||||
| CWIP ⓘ | 2 | 0 | 0 | 0 | ||||||
| Investmentsⓘ | 39 | 39 | 41 | 41 | ||||||
| Inventories | 47 | 36 | 29 | 48 | ||||||
| Trade Receivables | 31 | 52 | 74 | 113 | ||||||
| Cash Equivalents | 67 | 88 | 77 | 792 | ||||||
| Others Assetsⓘ | 297 | 386 | 502 | 726 | ||||||
| Total Assets ⓘ | 533 | 654 | 764 | 1,755 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -68 | -45 | -57 | -76 |
| PBT ⓘ | -18 | -41 | -12 | 24 |
| Adjustment ⓘ | -13 | -9 | -30 | -38 |
| Changes in Working Capital ⓘ | -37 | 6 | -12 | -60 |
| Tax Paid ⓘ | 0 | -1 | -3 | -2 |
| Cash Flow From Investing Activity ⓘ | -7 | -69 | -58 | -763 |
| Capex | -7 | -3 | -1 | -1 |
| Net Investments | -24 | -8 | -13 | -632 |
| Others ⓘ | 23 | -58 | -45 | -130 |
| Cash Flow From Financing Activityⓘ | 75 | 127 | 91 | 926 |
| Net Proceeds from Shares ⓘ | 0 | 4 | 0 | 1,000 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 62 | 18 |
| Interest Paid ⓘ | -2 | -5 | -11 | -22 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | 78 | 129 | 41 | -70 |
| Net Cash Flow ⓘ | 0 | 14 | -24 | 87 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 0 | 0 | 0 | 4.98 | ||||||
| ROCE (%) | -3.27 | -6.66 | -0.18 | 4.06 | ||||||
| Asset Turnover Ratio | 0.2 | 0.23 | 0.25 | 0.25 | ||||||
| PAT to CFO Conversion(x) | N/A | N/A | N/A | -2 | Working Capital Days | |||||
| Receivable Days | 107 | 110 | 130 | 108 | ||||||
| Inventory Days | 165 | 111 | 67 | 44 | ||||||
| Payable Days | 48 | 68 | 107 | 82 | ||||||
The company was incorporated as “Entero Healthcare Solutions Private Limited” as a private limited company under the Companies Act, 2013 pursuant to a certificate of incorporation dated January 10, 2018, issued by the Registrar of Companies, Central Registration Centre, under the administrative control of the Registrar of Companies, Delhi and Haryana at New Delhi. Thereafter, the company was converted into a public limited company pursuant to a special resolution passed in the annual general meeting of its Shareholders held on August 7, 2023, and consequently, the name of the company was changed to ‘Entero Healthcare Solutions Limited’, and a fresh certificate of incorporation dated August 25, 2023, was issued by the RoC.
The company was founded in 2018 by Prabhat Agrawal, its Promoter, Managing Director and Chief Executive Officer, and Prem Sethi, its Promoter, Whole-time Director and Chief Operating Officer, with the vision to create an organized, pan-India, technology driven and integrated healthcare products distribution platform that can add value to the entire healthcare ecosystem. The company adds value to the healthcare product manufacturers that work with it by providing them reach and accessibility to pharmacies, hospitals and clinics through its integrated and technology driven, pan-India healthcare products distribution platform. As of September 30, 2023, its 77 warehouses located across the country, last-mile delivery infrastructure and relationships with pharmacies, hospitals and clinics enables healthcare product manufacturers to make their products available to a wide range of customers. Similarly, the pharmacies, hospitals and clinics that its service get access to a wide range of healthcare products through its distribution infrastructure and its healthcare product manufacturer relationships.
Business area of the company
Entero Healthcare Solutions is one of India's largest and fastest growing healthcare products distribution platforms. The company offers both demand generation and demand fulfilment solutions to healthcare product manufacturers. It offers demand generation solutions to healthcare product manufacturers by promoting and creating awareness of their product brands to healthcare professionals, doctors and channels such as pharmacies, hospitals (both private and government), clinics and customers through e-commerce marketplaces. Further, it provides end-to-end healthcare products distribution solutions including imports, central warehousing, redistribution, last mile delivery and connection with the pharmacies, hospitals and clinics. Its demand generation and demand fulfilment solutions are integrated across the value chain and it benefit from synergies arising from its wide customer network, distribution infrastructure and geographic reach. The company’s scale of operations allows it to procure products at competitive prices and has a wide product range with adequate inventory levels. It also provides a diverse spectrum of healthcare products, including pharmaceutical products, nutraceuticals, medical devices, surgical consumables, over-the-counter medicines and vaccines, which enables it to become a one stop shop for its customer’s healthcare product needs.
Key awards, accreditations, and recognition
Major events and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
